Retinal Microglia Imaging for Early Neurodegenerative Disease Staging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing neurodegenerative diseases like Alzheimer's, Parkinson's, and glaucoma are delayed due to their silent and progressive nature, often leading to a lack of early detection and effective treatment.
Innovation Solution
A method is developed to determine the stage of neurodegenerative diseases by identifying the activation status of microglia cells in the eye using a wavelength-optimized apoptotic marker, such as annexin 5 labeled with D-776, and analyzing the pattern and number of amoeboid, ramified, or activated microglia through imaging techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If conventional diagnosis methods are used for neurodegenerative diseases, then the diagnosis can be performed with existing techniques, but the detection is delayed and occurs too late for effective intervention
Solution Approach 1:
The patent applies preliminary action by detecting microglia activation status and apoptotic cells in the retina before significant neuronal loss occurs. The method uses fluorescent markers (annexin V and Iba1) to identify early pathological changes in microglia cells and apoptotic retinal cells, allowing diagnosis at a pre-clinical stage when intervention can still prevent or slow disease progression. This shifts the detection window from late-stage neuronal death to early-stage cellular activation and apoptosis.
Solution Approach 2:
The patent uses microglia cells and apoptotic cells in the retina as intermediary biomarkers that indicate underlying neurodegenerative processes in the brain. These retinal cells serve as accessible proxies for detecting cerebral pathology, allowing non-invasive monitoring of disease progression and treatment response without directly measuring brain tissue changes.
2Measurement precision
If early detection methods using microglia imaging are implemented, then detection sensitivity improves, but the device complexity and measurement difficulty increase
Solution Approach 1:
The patent employs fluorescent markers that emit distinct colors to differentiate between cell types and states: annexin V conjugated to a fluorescent marker labels apoptotic cells, while Iba1 labels microglia cells. The imaging system captures these fluorescent signals to generate images showing the distribution and activation status of microglia and apoptotic cells in the retina, enabling precise disease staging through color-coded visual differentiation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for accurate monitoring of disease progression and treatment efficacy by differentiating between microglia states, providing early indicators of neurodegenerative diseases and enabling timely intervention.
Implementation Method 1
a labelled apoptotic marker, in particular annexin 5 conjugated to a wavelength-optimised label such as D-776
Implementation Method 2
identifying the activation status of microglia cells in a subject's eye by generating an image of the microglia cells using the labelled apoptotic marker
Data Source
AI summary
The invention relates to methods for determining the stage of a disease, particularly an ocular neurodegenerative disease such as Alzheimer's, Parkinson's, Huntington's and glaucoma, comprising the steps of identifying the status of microglial cells in the retina and relating that status to disease stage. Methods for identifying cells in the eye are also provided, as are labelled markers and the use thereof.